Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12 - PubMed (original) (raw)
Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12
Nathalie Schmitt et al. Immunity. 2009.
Abstract
T follicular helper (Tfh) cells help development of antibody responses via interleukin-21 (IL-21). Here we show that activated human dendritic cells (DCs) induced naive CD4(+) T cells to become IL-21-producing Tfh-like cells through IL-12. CD4(+) T cells primed with IL-12 induced B cells to produce immunoglobulins in a fashion dependent on IL-21 and inducible costimulator (ICOS), thus sharing fundamental characteristics with Tfh cells. The induction of Tfh-like cells by activated DCs was inhibited by neutralizing IL-12. IL-12 induced two different IL-21-producers: IL-21(+)IFN-gamma(+)T-bet(+) Th1 cells and IL-21(+)IFN-gamma(-)T-bet(-) non-Th1 cells, in a manner dependent on signal transducer and activator of transcription 4 (STAT4). IL-12 also regulated IL-21 secretion by memory CD4(+) T cells. Thus, IL-12 produced by activated DCs regulates antibody responses via developing IL-21-producing Tfh-like cells and inducing IL-21 secretion from memory CD4(+) T cells. These data suggest that the developmental pathway of Tfh cells differs between mice and humans, which have considerable implications for vaccine development.
Figures
Figure 1. IL-12 potently induces naïve CD4+ T cells to secrete IL-21
(A) Human naïve CD4+ T cells cultured with allogeneic DCs stimulated with LPS or CD40L were re-stimulated at day 7 with PMA + ionomycin to test intracellular IL-21 expression. Gated to FSChi activated CD4+ T cells. A representative out of three experiments. (B) Activated CD4+ T cells sorted at day 7 were re-stimulated with CD3 + CD28 mAbs 24 h to measure IL-21 secretion. (C) Naïve CD4+ T cells were stimulated by CD3 + CD28 mAbs with the supernatants of DCs activated by CD40L or TLR-ligands. IL-21 production from activated CD4+ T cells as in (B). (D) Naïve CD4+ T cells stimulated with CD3 + CD28 mAbs in the presence of the indicated cytokines and re-stimulated at day 7 with PMA + ionomycin for intracellular IL-21 expression. A representative out of three experiments. (E, F) IL-21 secretion from activated CD4+ T cells. Experiments performed with cells from five different donors are shown in (F). Paired _t_-test. (G) Expression of IL-21 in naïve CD4+ T cells primed with IL-21 (30 ng/ml) as in (D) (left). IL-21 secretion from the activated CD4+ T cells (right). A representative out of three experiments.
Figure 2. IL-12 induces two distinct types of IL-21-producers
(A) Naïve CD4+ T cells were stimulated with CD3 + CD28 mAbs for 7 d in the presence of titrated amounts of IL-12 or IL-23. IL-21 and IFN-γ secretion upon 24 h CD3 + CD28 restimulation. A representative out of two experiments. (B) Naïve CD4+ T cells stimulated with CD3 + CD28 mAbs in the presence of 10 ng/ml IL-12 or IL-23 were re-stimulated at day 7 with PMA + ionomycin to test intracellular cytokine expression. Gated to FSChi activated CD4+ T cells. A representative out of five experiments. (C) Intracellular cytokine expression in CD4+ T cells primed with titrated amounts of IL-12. After re-stimulation with PMA + ionomycin. A representative out of two experiments. (D) Highly purified cord blood naïve CD4+ T cells were stimulated for 7 d with CD3 + CD28 mAbs ± IL-12. Intracellular IL-21 and IFN-γ expression upon stimulation with PMA and ionomycin. A representative out of three experiments. (E) Expression of T-bet and intracytoplasmic cytokines was analyzed in CD4+ T cells primed with IL-12, after re-stimulation with PMA + ionomycin. The levels of T-bet expression in IL-21+IFN-γ- (R1), IL-21-IFN-γ+ (R2) and IL-21+IFN-γ+ (R3) cells were compared to that in IL-21-IFN-γ- cells (R0). (F) Expression of T-bet and intracytoplasmic cytokines was analyzed in tonsillar CD4+ T cells stimulated with PMA + ionomycin. (G) Naïve CD4+ T cells were cultured for 7 d with CD3 + CD28 mAbs under Th0, Th1, Th2, or Th17-skewing conditions. IL-21 secretion upon 24 h CD3 + CD28 restimulation from activated CD4+ T cells.
Figure 3. CD4+ T cells primed in the presence of IL-12 help B cells
(A) Naive B cells pre-activated with anti-IgM were cultured in the presence of CpG and SEB with autologous CD4+ T cells primed with the indicated cytokines. Ig titers in the supernatants were measured at day 14. Mean ± s.e.m. n=6. Unpaired two-tailed _t_-test. A representative out of three experiments. (B) Memory B cells were cultured in the presence of SEB with autologous CD4+ T cells primed with the indicated cytokines. Ig levels at day 14. Mean ± s.e.m. n=6. Unpaired two-tailed _t_-test. A representative out of three experiments. (C) Ig secretion from memory B cells cultured with CD4+ T cells primed with titrated amounts of IL-12. A representative out of two experiments. (D) IL-21R-Fc was added to block IL-21 to the co-cultures of memory B cells and CD4+ T cells primed with IL-12. Ig levels at day 14. Mean ± s.e.m. n=6. Unpaired two-tailed _t_-test. A representative out of three experiments. (E) Blocking of ICOS by ICOS-L-mIgFc during T-B cultures. Ig levels at day 14. Mean ± s.e.m. n=6. Unpaired two-tailed _t_-test. A representative out of three experiments.
Figure 4. DCs exposed to bacteria induce IL-21-producing Tfh-like cells through IL-12
(A) IL-21 secretion from naïve CD4+ T cells cultured with allogeneic DCs exposed to heat-killed bacteria. A representative out of five experiments. (B) IL-12 and IL-23 secretion from DCs exposed to heat-killed bacteria. A representative out of five experiments. (C) IL-21 secretion of CD4+ T cells primed with bacteria-exposed DCs in the presence of anti IL-12p40 or IL-12p70 mAb. A representative out of five experiments. (D) IL-21 secretion of CD4+ T cells primed with CD40L- or LPS-activated DCs in the presence of anti IL-12p70 mAb. A representative out of three experiments. (E) IL-12 secretion from DCs exposed to CD40L or TLR-ligands. A representative out of three experiments. (F) Naïve CD4+ T cells were cultured for 7 d with allogeneic bacteria-exposed DCs in the presence of anti IL-12p40 or IL-12p70 mAbs. Activated CD4+ T cells were sorted and cultured with autologous memory B cells, and produced Igs were analyzed. Mean ± s.e.m. n=6. Unpaired two-tailed _t_-test. A representative out of four experiments.
Figure 5. IL-12 promotes IL-21 secretion by blood memory CD4+ T cells
(A, B) Fresh PBMCs were stimulated with SEB in the presence of anti IL-12p40 or IL-12p70 mAb. IL-21 (A) or the indicated cytokines (B) secreted cytokines during 48 h cultures were measured. Symbols represent results from seven different donors. (C) Memory CD4+ T cells were stimulated with CD3 + CD28 mAbs in the presence of the indicated cytokines. IL-21 secretion in the supernatants was measured at 24 and 48 h of culture. (D) Naive CD4+ T cells were stimulated with CD3 + CD28 mAbs in the presence IL-12. IL-21 secretion in the supernatants was measured at the indicated time points.
Figure 6. IL-12 induce IL-21 producers through STAT4
(A) Naïve CD4+ T cells stimulated with CD3 + CD28 mAbs for 5-7 d were transfected with siRNA specific for STAT3 or STAT4. The levels of STAT3 and STAT4 expression at 24 h post-transfection were analyzed by flow cytometry. Cells transfected with control siRNA (gray), STAT3 siRNA (blue), and STAT4 siRNA (red) are shown. Black histogram represents staining with control isotype. Gated to AQUA-FSChi activated CD4+ T cells. A representative out of three experiments. (B) Transfected CD4+ T cells were cultured for 48 h in the presence of IL-12, IL-23 or IL-21. Activated CD4+ T cells were then re-stimulated with CD3 + CD28 mAbs for 24 h to measure IL-21 secretion. A representative out of three experiments. (C) After 48 h culture with IL-12, IL-23, or IL-21, the expression of IL-21 was analyzed after 6h restimulation with PMA + ionomycin. Gated to AQUA-FSChi activated CD4+ T cells. A representative out of three experiments. (D) Percentages of IL-21-expressing CD4+ T cells in three independent experiments. (E) Percentages of IFNγ+IL-21+ and IFNγ-IL-21+ cells in STAT4 siRNA-transfected CD4+ T cells cultured with IL-12.
Comment in
- Helping the helpers!
Ma CS, Tangye SG. Ma CS, et al. Immunity. 2009 Jul 17;31(1):12-4. doi: 10.1016/j.immuni.2009.06.009. Immunity. 2009. PMID: 19604489
Similar articles
- Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors.
Ma X, Nakayamada S, Kubo S, Sakata K, Yamagata K, Miyazaki Y, Yoshikawa M, Kitanaga Y, Zhang M, Tanaka Y. Ma X, et al. Ann Rheum Dis. 2018 Sep;77(9):1354-1361. doi: 10.1136/annrheumdis-2017-212652. Epub 2018 May 31. Ann Rheum Dis. 2018. PMID: 29853448 - STAT4 and T-bet control follicular helper T cell development in viral infections.
Weinstein JS, Laidlaw BJ, Lu Y, Wang JK, Schulz VP, Li N, Herman EI, Kaech SM, Gallagher PG, Craft J. Weinstein JS, et al. J Exp Med. 2018 Jan 2;215(1):337-355. doi: 10.1084/jem.20170457. Epub 2017 Dec 6. J Exp Med. 2018. PMID: 29212666 Free PMC article. - Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies.
Martin-Gayo E, Gao C, Chen HR, Ouyang Z, Kim D, Kolb KE, Shalek AK, Walker BD, Lichterfeld M, Yu XG. Martin-Gayo E, et al. Cell Rep. 2020 Jan 28;30(4):984-996.e4. doi: 10.1016/j.celrep.2019.12.087. Cell Rep. 2020. PMID: 31995767 Free PMC article. - Role of TRAFs in Signaling Pathways Controlling T Follicular Helper Cell Differentiation and T Cell-Dependent Antibody Responses.
Pedros C, Altman A, Kong KF. Pedros C, et al. Front Immunol. 2018 Oct 22;9:2412. doi: 10.3389/fimmu.2018.02412. eCollection 2018. Front Immunol. 2018. PMID: 30405612 Free PMC article. Review. - Follicular helper T cell in immunity and autoimmunity.
Mesquita D Jr, Cruvinel WM, Resende LS, Mesquita FV, Silva NP, Câmara NO, Andrade LE. Mesquita D Jr, et al. Braz J Med Biol Res. 2016;49(5):e5209. doi: 10.1590/1414-431X20165209. Epub 2016 Apr 19. Braz J Med Biol Res. 2016. PMID: 27096200 Free PMC article. Review.
Cited by
- The differentiation courses of the Tfh cells: a new perspective on autoimmune disease pathogenesis and treatment.
Yang Q, Zhang F, Chen H, Hu Y, Yang N, Yang W, Wang J, Yang Y, Xu R, Xu C. Yang Q, et al. Biosci Rep. 2024 Jan 31;44(1):BSR20231723. doi: 10.1042/BSR20231723. Biosci Rep. 2024. PMID: 38051200 Free PMC article. Review. - A novel memory-like Tfh cell subset is precursor to effector Tfh cells in recall immune responses.
Feng H, Zhao Z, Zhao X, Bai X, Fu W, Zheng L, Kang B, Wang X, Zhang Z, Dong C. Feng H, et al. J Exp Med. 2024 Jan 1;221(1):e20221927. doi: 10.1084/jem.20221927. Epub 2023 Dec 4. J Exp Med. 2024. PMID: 38047912 Free PMC article. - CD4+ T-cell subsets in autoimmune hepatitis: A review.
Chen H, Han Z, Fan Y, Chen L, Peng F, Cheng X, Wang Y, Su J, Li D. Chen H, et al. Hepatol Commun. 2023 Sep 11;7(10):e0269. doi: 10.1097/HC9.0000000000000269. eCollection 2023 Oct 1. Hepatol Commun. 2023. PMID: 37695088 Free PMC article. Review. - Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.
Kawahata K, Ishii T, Gono T, Tsuchiya Y, Ohashi H, Yoshizawa K, Zheng R, Ayabe M, Nishikawa K. Kawahata K, et al. RMD Open. 2023 Aug;9(3):e003268. doi: 10.1136/rmdopen-2023-003268. RMD Open. 2023. PMID: 37652554 Free PMC article. Clinical Trial. - Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13.
Azarias Da Silva M, Nioche P, Soudaramourty C, Bull-Maurer A, Tiouajni M, Kong D, Zghidi-Abouzid O, Picard M, Mendes-Frias A, Santa-Cruz A, Carvalho A, Capela C, Pedrosa J, Castro AG, Loubet P, Sotto A, Muller L, Lefrant JY, Roger C, Claret PG, Duvnjak S, Tran TA, Tokunaga K, Silvestre R, Corbeau P, Mammano F, Estaquier J. Azarias Da Silva M, et al. Sci Adv. 2023 Aug 4;9(31):eadg2122. doi: 10.1126/sciadv.adg2122. Epub 2023 Aug 4. Sci Adv. 2023. PMID: 37540749 Free PMC article.
References
- Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S. The CD40 antigen and its ligand. Annual review of immunology. 1994;12:881–922. - PubMed
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U19 AI057234-04/AI/NIAID NIH HHS/United States
- P01 CA084512-05A29004/CA/NCI NIH HHS/United States
- P01 CA084512-030003/CA/NCI NIH HHS/United States
- P01 CA084512-020003/CA/NCI NIH HHS/United States
- R01 CA078846-07/CA/NCI NIH HHS/United States
- P01 CA084512/CA/NCI NIH HHS/United States
- R01 CA078846-01A1/CA/NCI NIH HHS/United States
- R01 CA078846-09/CA/NCI NIH HHS/United States
- U19 AI057234-05S1/AI/NIAID NIH HHS/United States
- U19 AI057234-010004/AI/NIAID NIH HHS/United States
- U19 AI057234-03/AI/NIAID NIH HHS/United States
- U19 AI057234-010005/AI/NIAID NIH HHS/United States
- P01 CA084512-069004/CA/NCI NIH HHS/United States
- U19 AI057234-02/AI/NIAID NIH HHS/United States
- U19 AI057234-05S10012/AI/NIAID NIH HHS/United States
- P01 CA084512-060005/CA/NCI NIH HHS/United States
- R01 CA078846-04/CA/NCI NIH HHS/United States
- U19 AI057234-01/AI/NIAID NIH HHS/United States
- P01 CA084512-01A10003/CA/NCI NIH HHS/United States
- P01 CA084512-05A2/CA/NCI NIH HHS/United States
- R01 CA078846-05/CA/NCI NIH HHS/United States
- R01 CA078846-08/CA/NCI NIH HHS/United States
- P01 CA084512-079004/CA/NCI NIH HHS/United States
- U19-AI057234/AI/NIAID NIH HHS/United States
- U19 AI057234-05/AI/NIAID NIH HHS/United States
- R01-CA078846/CA/NCI NIH HHS/United States
- R01 CA078846-10/CA/NCI NIH HHS/United States
- P01 CA084512-06/CA/NCI NIH HHS/United States
- R01 CA078846-06/CA/NCI NIH HHS/United States
- U19 AI057234-010006/AI/NIAID NIH HHS/United States
- P01 CA084512-079002/CA/NCI NIH HHS/United States
- P01 CA084512-069002/CA/NCI NIH HHS/United States
- U19 AI057234-05S19003/AI/NIAID NIH HHS/United States
- R01-CA84512/CA/NCI NIH HHS/United States
- R01 CA078846-02/CA/NCI NIH HHS/United States
- U19 AI057234/AI/NIAID NIH HHS/United States
- P01 CA084512-05A29002/CA/NCI NIH HHS/United States
- R01 CA078846-03/CA/NCI NIH HHS/United States
- R01 CA078846/CA/NCI NIH HHS/United States
- U19 AI057234-05S10013/AI/NIAID NIH HHS/United States
- P01 CA084512-070005/CA/NCI NIH HHS/United States
- P01 CA084512-07/CA/NCI NIH HHS/United States
- P01 CA084512-040003/CA/NCI NIH HHS/United States
- P01 CA084512-05A20005/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous